Ann E. Berman Buys 57,965 Shares of Immuneering Co. (NASDAQ:IMRX) Stock

Immuneering Co. (NASDAQ:IMRXGet Free Report) Director Ann E. Berman acquired 57,965 shares of the business’s stock in a transaction dated Monday, March 18th. The shares were bought at an average price of $2.13 per share, for a total transaction of $123,465.45. Following the acquisition, the director now owns 67,465 shares of the company’s stock, valued at $143,700.45. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Immuneering Stock Performance

Immuneering stock opened at $2.78 on Thursday. Immuneering Co. has a 12 month low of $1.90 and a 12 month high of $14.29. The stock’s 50 day simple moving average is $5.85 and its two-hundred day simple moving average is $6.58.

Immuneering (NASDAQ:IMRXGet Free Report) last released its quarterly earnings data on Friday, March 1st. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.06). As a group, equities research analysts expect that Immuneering Co. will post -1.89 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Cormorant Asset Management LP lifted its position in shares of Immuneering by 76.2% during the 2nd quarter. Cormorant Asset Management LP now owns 4,204,364 shares of the company’s stock valued at $42,632,000 after buying an additional 1,818,183 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in Immuneering by 16.2% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 4,142,829 shares of the company’s stock valued at $22,413,000 after purchasing an additional 577,356 shares during the last quarter. BlackRock Inc. raised its stake in Immuneering by 80.8% in the 2nd quarter. BlackRock Inc. now owns 2,423,658 shares of the company’s stock valued at $24,576,000 after purchasing an additional 1,083,465 shares during the last quarter. Citadel Advisors LLC raised its stake in Immuneering by 1.8% in the 2nd quarter. Citadel Advisors LLC now owns 2,199,209 shares of the company’s stock valued at $11,898,000 after purchasing an additional 39,777 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Immuneering by 2.9% in the 4th quarter. Vanguard Group Inc. now owns 1,073,815 shares of the company’s stock valued at $7,893,000 after purchasing an additional 29,963 shares during the last quarter. Hedge funds and other institutional investors own 58.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on IMRX. TD Cowen restated a “market perform” rating on shares of Immuneering in a report on Friday, March 15th. Chardan Capital cut their price objective on shares of Immuneering from $21.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, March 15th. Jefferies Financial Group restated a “hold” rating and set a $3.00 price objective (down previously from $16.00) on shares of Immuneering in a report on Friday, March 15th. Guggenheim restated a “neutral” rating on shares of Immuneering in a report on Thursday, March 14th. Finally, Needham & Company LLC cut their price objective on shares of Immuneering from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, March 15th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $15.50.

View Our Latest Stock Analysis on Immuneering

About Immuneering

(Get Free Report)

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 currently in Investigational New Drug application to treat solid tumors.

Featured Articles

Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.